Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice

Science Signaling

Volumn 5, Issue 217, 2012, Pages

  Menon, Suchithra ^a   Yecies, Jessica L ^a   Zhang, Hui H ^a   Howell, Jessica J ^a   Nicholatos, Justin ^a   Harputlugil, Eylul ^a   Bronson, Roderick T ^b   Kwiatkowski, David J ^c   Manning, Brendan D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; TUBERIN; ANTINEOPLASTIC ANTIBIOTIC; CYCLINE; MTORC1 COMPLEX, MOUSE; MULTIPROTEIN COMPLEX; PROTEIN; TORC1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DIET; ENVIRONMENTAL FACTOR; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER INJURY; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE COURSE; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; GENETICS; IMMUNOBLOTTING; LIVER; LIVER CELL; LIVER TUMOR; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

MAMMALIA; MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM STRESS; FEMALE; HEPATOCYTES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84859090262     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002739     Document Type: Article

References (100)

1. World Health Organization, Mortality Database; http://www.who.int/whosis/ en.
2. D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
3. F. Pons-Renedo, J. M. Llovet, Hepatocellular carcinoma: Aclinical update. MedGenMed 5, 11 (2003).
4. H. B. El-Serag, K. L. Rudolph, Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
5. M. Sherman, Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 30, 3-16 (2010).
6. S. H. Caldwell, D. M. Crespo, H. S. Kang, A. M. Al-Osaimi, Obesity and hepatocellular carcinoma. Gastroenterology 127, S97-S103 (2004).
7. N. Fausto, Mouse liver tumorigenesis: Models, mechanisms, and relevance to human disease. Semin. Liver Dis. 19, 243-252 (1999).
8. S. S. Thorgeirsson, J. W. Grisham, Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 339-346 (2002).
9. P. A. Farazi, R. A. DePinho, Hepatocellular carcinoma pathogenesis: From genes to environment. Nat. Rev. Cancer 6, 674-687 (2006).
10. E. Bugianesi, Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11, 191-207 (2007).
11. G. K. Anagnostopoulos, D. Arvanitidis, S. Tsiakos, G. Margantinis, K. Grigoriadis, P. Kostopoulos, Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? J. Clin. Gastroenterol. 37, 88-89 (2003).
12. E. E. Calle, R. Kaaks, Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
13. S. Parekh, F. A. Anania, Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology 132, 2191-2207 (2007).
14. B. Q. Starley, C. J. Calcagno, S. A. Harrison, Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 51, 1820-1832 (2010).
15. E. J. Park, J. H. Lee, G. Y. Yu, G. He, S. R. Ali, R. G. Holzer, C. H. Osterreicher, H. Takahashi, M. Karin, Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
16. U. Ariz, J. M. Mato, S. C. Lu, M. L. Martínez Chantar, Nonalcoholic steatohepatitis, animal models, and biomarkers: What is new? Methods Mol. Biol. 593, 109-136 (2010).
17. S. H. Um, F. Frigerio, M. Watanabe, F. Picard, M. Joaquin, M. Sticker, S. Fumagalli, P. R. Allegrini, S. C. Kozma, J. Auwerx, G. Thomas, Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205 (2004).
18. L. Khamzina, A. Veilleux, S. Bergeron, A. Marette, Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: Possible involvement in obesity-linked insulin resistance. Endocrinology 146, 1473-1481 (2005).
19. S. Menon, B. D. Manning, Common corruption of the mTOR signaling network in human tumors. Oncogene 27 (Suppl. 2), S43-S51 (2008).
20. A. Villanueva, D. Y. Chiang, P. Newell, J. Peix, S. Thung, C. Alsinet, V. Tovar, S. Roayaie, B. Minguez, M. Sole, C. Battiston, S. Van Laarhoven, M. I. Fiel, A. Di Feo, Y. Hoshida, S. Yea, S. Toffanin, A. Ramos, J. A. Martignetti, V. Mazzaferro, J. Bruix, S. Waxman, M. Schwartz, M. Meyerson, S. L. Friedman, J. M. Llovet, Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-1983.e11 (2008).
21. L. Zhou, Y. Huang, J. Li, Z. Wang, The mTOR pathway isassociated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol. 27, 255-261 (2010).
22. W. Sieghart, T. Fuereder, K. Schmid, D. Cejka, J. Werzowa, F. Wrba, X. Wang, D. Gruber, S. Rasoul-Rockenschaub, M. Peck-Radosavljevic, V. Wacheck, Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83, 425-432 (2007).
23. H. A. Baba, J. Wohlschlaeger, V. R. Cicinnati, P. Hilgard, H. Lang, G. C. Sotiropoulos, A. Takeda, S. Beckebaum, K. J. Schmitz, Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. 29, 399-405 (2009).
24. F. Sahin, R. Kannangai, O. Adegbola, J. Wang, G. Su, M. Torbenson, mTOR and P70 S6kinase expression in primary liver neoplasms. Clin. Cancer Res. 10, 8421-8425 (2004).
25. T. Kawahara, S. Asthana, N. M. Kneteman, m-TOR inhibitors: What role in liver transplantation? J. Hepatol. 55, 1441-1451 (2011).
26. G. Treiber, mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev. Anticancer Ther. 9, 247-261 (2009).
27. P. Mannová, L. Beretta, Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication. J. Virol. 79, 8742-8749 (2005).
28. L. Peng, D. Liang, W. Tong, J. Li, Z. Yuan, Hepatitis Cvirus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J. Biol. Chem. 285, 20870-20881 (2010).
29. H. Ishida, K. Li, M. Yi, S. M. Lemon, p21-activated kinase 1is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J. Biol. Chem. 282, 11836-11848 (2007).
30. J. Huang, B. D. Manning, The TSC1-TSC2 complex: Amolecular switchboard controlling cell growth. Biochem. J. 412, 179-190 (2008).
31. L. Meikle, J. R. McMullen, M. C. Sherwood, A. S. Lader, V. Walker, J. A. Chan, D. J. Kwiatkowski, A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum. Mol. Genet. 14, 429-435 (2005).
32. L.Meikle, D.M. Talos, H. Onda, K. Pollizzi, A. Rotenberg,M. Sahin, F. E. Jensen, D. J. Kwiatkowski, A mouse model of tuberous sclerosis: Neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 27, 5546-5558 (2007).
33. L. Rachdi, N. Balcazar, F. Osorio-Duque, L. Elghazi, A. Weiss, A. Gould, K. J. Chang-Chen, M. J. Gambello, E. Bernal-Mizrachi, Disruption of Tsc2 in pancreatic β cells induces βcell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 105, 9250-9255 (2008).
34. H. Mori, K. Inoki, H. Munzberg, D. Opland, M. Faouzi, E. C. Villanueva, T. Ikenoue, D. Kwiatkowski, O. A. MacDougald, M. G. Myers Jr., K. L. Guan, Critical role for hypothalamic mTOR activity in energy balance. Cell Metab. 9, 362-374 (2009).
35. H. Mori, K. Inoki, D. Opland, H. Munzberg, E. C. Villanueva, M. Faouzi, T. Ikenoue, D. Kwiatkowski, O. A. Macdougald, M. G. Myers Jr., K. L. Guan, Critical roles for the TSC-mTOR pathway in β-cell function. Am. J. Physiol. Endocrinol. Metab. 297, E1013-E1022 (2009).
36. S. Sengupta, T. R. Peterson, M. Laplante, S. Oh, D. M. Sabatini, mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468, 1100-1104 (2010).
37. K. Inoki, H. Mori, J. Wang, T. Suzuki, S. Hong, S. Yoshida, S. M. Blattner, T. Ikenoue, M. A. Ruegg, M. N. Hall, D. J. Kwiatkowski, M. P. Rastaldi, T. B. Huber, M. Kretzler, L. B. Holzman, R. C. Wiggins, K. L. Guan, mTORC1 activation inpodocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181-2196 (2011).
38. J. L. Yecies, H. H. Zhang, S. Menon, S. Liu, D. Yecies, A. I. Lipovsky, C. Gorgun, D. J. Kwiatkowski, G. S. Hotamisligil, C. H. Lee, B. D. Manning, Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14, 21-32 (2011).
39. J. Goto, D. M. Talos, P. Klein, W. Qin, Y. I. Chekaluk, S. Anderl, I. A. Malinowska, A. Di Nardo, R. T. Bronson, J. A. Chan, H. V. Vinters, S. G. Kernie, F. E. Jensen, M. Sahin, D. J. Kwiatkowski, Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc. Natl. Acad. Sci. U.S.A. 108, E1070-E1079 (2011).
40. Y. Totoki, K. Tatsuno, S. Yamamoto, Y. Arai, F. Hosoda, S. Ishikawa, S. Tsutsumi, K. Sonoda, H. Totsuka, T. Shirakihara, H. Sakamoto, L. Wang, H. Ojima, K. Shimada, T. Kosuge, T. Okusaka, K. Kato, J. Kusuda, T. Yoshida, H. Aburatani, T. Shibata, High-resolution characterization of ahepatocellular carcinoma genome. Nat. Genet. 43, 464-469 (2011).
41. H. Malhi, R. J. Kaufman, Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795-809 (2011).
42. E. White, C. Karp, A. M. Strohecker, Y. Guo, R. Mathew, Role of autophagy in suppression of inflammation and cancer. Curr. Opin. Cell Biol. 22, 212-217 (2010).
43. A. Takamura, M. Komatsu, T. Hara, A. Sakamoto, C. Kishi, S.Waguri, Y. Eishi, O. Hino, K. Tanaka, N. Mizushima, Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25, 795-800 (2011).
44. K. G. Ishak, P. P. Anthony, L. H. Sobin, Histological Typing of Tumours of the Liver (WHO, Geneva, Switzerland, ed. 2, 1994), pp. 11-17.
45. K. Nakanishi, M. Sakamoto, S. Yamasaki, S. Todo, S. Hirohashi, Akt phosphorylation is arisk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103, 307-312 (2005).
46. S. Boyault, D. S. Rickman, A. de Reyniès, C. Balabaud, S. Rebouissou, E. Jeannot, A. Hérault, J. Saric, J. Belghiti, D. Franco, P. Bioulac-Sage, P. Laurent-Puig, J. Zucman-Rossi, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007).
47. S. Whittaker, R. Marais, A. X. Zhu, The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010).
48. E. Pikarsky, R. M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun, Y. Ben-Neriah, NF-κB functions as atumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004).
49. J. Haybaeck, N. Zeller, M. J. Wolf, A. Weber, U. Wagner, M. O. Kurrer, J. Bremer, G. Iezzi, R. Graf, P. A. Clavien, R. Thimme, H. Blum, S. A. Nedospasov, K. Zatloukal, M. Ramzan, S. Ciesek, T. Pietschmann, P. N. Marche, M. Karin, M. Kopf, J. L. Browning, A. Aguzzi, M. Heikenwalder, A lymphotoxin-driven pathway tohepatocellular carcinoma. Cancer Cell 16, 295-308 (2009).
50. T. Luedde, R. F. Schwabe, NF-kB in the liver-Linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 108-118 (2011).
51. T. Luedde, N. Beraza, V. Kotsikoris, G. van Loo, A. Nenci, R. De Vos, T. Roskams, C. Trautwein, M. Pasparakis, Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119-132 (2007).
52. S. Maeda, H. Kamata, J. L. Luo, H. Leffert, M. Karin, IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990 (2005).
53. G. He, M. Karin, NF-κB and STAT3 -Key players in liver inflammation and cancer. Cell Res. 21, 159-168 (2011).
54. G. He, G. Y. Yu, V. Temkin, H. Ogata, C. Kuntzen, T. Sakurai, W. Sieghart, M. Peck-Radosavljevic, H. L. Leffert, M. Karin, Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286-297 (2010).
55. D. F. Calvisi, S. Ladu, A. Gorden, M. Farina, E. A. Conner, J. S. Lee, V. M. Factor, S. S. Thorgeirsson, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130, 1117-1128 (2006).
56. K. Düvel, J. L. Yecies, S. Menon, P. Raman, A. I. Lipovsky, A. L. Souza, E. Triantafellow, Q. Ma, R. Gorski, S. Cleaver, M. G. Vander Heiden, J. P. MacKeigan, P. M. Finan, C. B. Clish, L. O. Murphy, B. D. Manning, Activation of ametabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010).
57. J. L. Yecies, B. D. Manning, Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 71, 2815-2820 (2011).
58. M. R. Alison, M. J. Lovell, Liver cancer: The role of stem cells. Cell Prolif. 38, 407-421 (2005).
59. S. Benhamouche, M. Curto, I. Saotome, A. B. Gladden, C. H. Liu, M. Giovannini, A. I. McClatchey, Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718-1730 (2010).
60. S. Sell, H. L. Leffert, An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology 2, 77-86 (1982).
61. H. Song, K. K. Mak, L. Topol, K. Yun, J. Hu, L. Garrett, Y. Chen, O. Park, J. Chang, R. M. Simpson, C. Y. Wang, B. Gao, J. Jiang, Y. Yang, Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 107, 1431-1436 (2010).
62. L. Lu, Y. Li, S. M. Kim, W. Bossuyt, P. Liu, Q. Qiu, Y. Wang, G. Halder, M. J. Finegold, J. S. Lee, R. L. Johnson, Hippo signaling is apotent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. U.S.A. 107, 1437-1442 (2010).
63. G. S. Hotamisligil, Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917 (2010).
64. U. Ozcan, Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Gorgun, L. H. Glimcher, G. S. Hotamisligil, Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461 (2004).
65. U. Ozcan, L. Ozcan, E. Yilmaz, K. Duvel, M. Sahin, B. D. Manning, G. S. Hotamisligil, Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29, 541-551 (2008).
66. A. Di Nardo, I. Kramvis, N. Cho, A. Sadowski, L. Meikle, D. J. Kwiatkowski, M. Sahin, Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J. Neurosci. 29, 5926-5937 (2009).
67. J. D. Rabinowitz, E. White, Autophagy and metabolism. Science 330, 1344-1348 (2010).
68. A. C. Kimmelman, The dynamic nature of autophagy in cancer. Genes Dev. 25, 1999-2010 (2011).
69. L. Yang, P. Li, S. Fu, E. S. Calay, G. S. Hotamisligil, Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 11, 467-478 (2010).
70. M. J. Czaja, Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 140, 1895-1908 (2011).
71. T. P. Neufeld, TOR-dependent control of autophagy: Biting the hand that feeds. Curr. Opin. Cell Biol. 22, 157-168 (2010).
72. J. Kim, M. Kundu, B. Viollet, K. L. Guan, AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132-141 (2011).
73. S. Ng, Y. T. Wu, B. Chen, J. Zhou, H. M. Shen, Impaired autophagy due toconstitutive mTOR activation sensitizes TSC2-null cells to cell death under stress. Autophagy 7, 1173-1186 (2011).
74. A. Parkhitko, F. Myachina, T. A. Morrison, K. M. Hindi, N. Auricchio, M. Karbowniczek, J. J. Wu, T. Finkel, D. J. Kwiatkowski, J. J. Yu, E. P. Henske, Tumorigenesis intuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc. Natl. Acad. Sci. U.S.A. 108, 12455-12460 (2011).
75. M. Komatsu, S. Waguri, M. Koike, Y. S. Sou, T. Ueno, T. Hara, N. Mizushima, J. Iwata, J. Ezaki, S. Murata, J. Hamazaki, Y. Nishito, S. Iemura, T. Natsume, T. Yanagawa, J. Uwayama, E.Warabi, H. Yoshida, T. Ishii, A. Kobayashi, M. Yamamoto, Z. Yue, Y. Uchiyama, E. Kominami, K. Tanaka, Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131, 1149-1163 (2007).
76. X. Qu, J. Yu, G. Bhagat, N. Furuya, H. Hibshoosh, A. Troxel, J. Rosen, E. L. Eskelinen, N. Mizushima, Y. Ohsumi, G. Cattoretti, B. Levine, Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 112, 1809-1820 (2003).
77. Z. Yue, S. Jin, C. Yang, A. J. Levine, N. Heintz, Beclin 1,an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 100, 15077-15082 (2003).
78. Y. Inami, S. Waguri, A. Sakamoto, T. Kouno, K. Nakada, O. Hino, S. Watanabe, J. Ando, M. Iwadate, M. Yamamoto, M. S. Lee, K. Tanaka, M. Komatsu, Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J. Cell Biol. 193, 275-284 (2011).
79. G. Bjørkøy, T. Lamark, T. Johansen, p62/SQSTM1: Amissing link between protein aggregates and the autophagy machinery. Autophagy 2, 138-139 (2006).
80. V. Kirkin, T. Lamark, Y. S. Sou, G. Bjørkøy, J. L. Nunn, J. A. Bruun, E. Shvets, D. G. McEwan, T. H. Clausen, P. Wild, I. Bilusic, J. P. Theurillat, A. Overvatn, T. Ishii, Z. Elazar, M. Komatsu, I. Dikic, T. Johansen, A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol. Cell 33, 505-516 (2009).
81. K. Zatloukal, S. W. French, C. Stumptner, P. Strnad, M. Harada, D. M. Toivola, M. Cadrin, M. B. Omary, From Mallory toMallory-Denk bodies:What, how and why? Exp. Cell Res. 313, 2033-2049 (2007).
82. R. Mathew, C. M. Karp, B. Beaudoin, N. Vuong, G. Chen, H. Y. Chen, K. Bray, A. Reddy, G. Bhanot, C. Gelinas, R. S. Dipaola, V. Karantza-Wadsworth, E. White, Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062-1075 (2009).
83. B. Sun, M. Karin, Obesity, inflammation, and liver cancer. J. Hepatol. 56, 704-713 (2012).
84. M. J. Bouchard, S. Navas-Martin, Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett. 305, 123-143 (2011).
85. A. Villanueva, P. Newell, D. Y. Chiang, S. L. Friedman, J. M. Llovet, Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007).
86. J. J. Bae, J. W. Rho, T. J. Lee, S. S. Yun, H. J. Kim, J. H. Choi, D. Jeong, B. C. Jang, T. Y. Lee, Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol. Rep. 18, 1007-1013 (2007).
87. L. Wang, W. L. Wang, Y. Zhang, S. P. Guo, J. Zhang, Q. L. Li, Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37, 389-396 (2007).
88. T. H. Hu, C. C. Huang, P. R. Lin, H. W. Chang, L. P. Ger, Y. W. Lin, C. S. Changchien, C. M. Lee, M. H. Tai, Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97, 1929-1940 (2003).
89. T. H. Hu, C. C. Wang, C. C. Huang, C. L. Chen, C. H. Hung, C. H. Chen, J. H. Wang, S. N. Lu, C. M. Lee, C. S. Changchien, M. H. Tai, Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol. Rep. 18, 1417-1426 (2007).
90. B. Stiles, Y.Wang, A. Stahl, S. Bassilian, W. P. Lee, Y. J. Kim, R. Sherwin, S. Devaskar, R. Lesche, M. A. Magnuson, H. Wu, Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 101, 2082-2087 (2004).
91. V. A. Galicia, L. He, H. Dang, G. Kanel, C. Vendryes, B. A. French, N. Zeng, J. A. Bayan, W. Ding, K. S. Wang, S. French, M. J. Birnbaum, C. B. Rountree, B. L. Stiles, Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 139, 2170-2182 (2010).
92. Y. Horie, A. Suzuki, E. Kataoka, T. Sasaki, K. Hamada, J. Sasaki, K. Mizuno, G. Hasegawa, H. Kishimoto, M. Iizuka, M. Naito, K. Enomoto, S. Watanabe, T. W. Mak, T. Nakano, Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774-1783 (2004).
93. S. Watanabe, Y. Horie, A. Suzuki, Hepatocyte-specific Pten-deficient mice asa novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 33, 161-166 (2005).
94. N. Fausto, J. S. Campbell, K. J. Riehle, Liver regeneration. Hepatology 43, S45-S53 (2006).
95. D. Moradpour, F. Penin, C. M. Rice, Replication of hepatitis Cvirus. Nat. Rev. Microbiol. 5, 453-463 (2007).
96. N. L. Benali-Furet, M. Chami, L. Houel, F. De Giorgi, F. Vernejoul, D. Lagorce, L. Buscail, R. Bartenschlager, F. Ichas, R. Rizzuto, P. Paterlini-Brechot, Hepatitis Cvirus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene 24, 4921-4933 (2005).
97. X. H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, B. Levine, Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672-676 (1999).
98. R. Mathew, S. Kongara, B. Beaudoin, C. M. Karp, K. Bray, K. Degenhardt, G. Chen, S. Jin, E. White, Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 21, 1367-1381 (2007).
99. V. Karantza-Wadsworth, S. Patel, O. Kravchuk, G. Chen, R. Mathew, S. Jin, E. White, Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 21, 1621-1635 (2007).
100. D. J. Kwiatkowski, H. Zhang, J. L. Bandura, K. M. Heiberger, M. Glogauer, N. el-Hashemite, H. Onda, A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11, 525-534 (2002).